In a report released today, Sean Dodge from RBC Capital maintained a Buy rating on R1 RCM (RCM – Research Report), with a price target of $19.00. The company’s shares closed yesterday at $12.15.
Dodge covers the Healthcare sector, focusing on stocks such as Sotera Health, R1 RCM, and Catalent. According to TipRanks, Dodge has an average return of -7.5% and a 38.46% success rate on recommended stocks.
Currently, the analyst consensus on R1 RCM is a Moderate Buy with an average price target of $16.75, a 37.86% upside from current levels. In a report released on April 5, Guggenheim also maintained a Buy rating on the stock with a $15.00 price target.
The company has a one-year high of $18.71 and a one-year low of $8.87. Currently, R1 RCM has an average volume of 3.69M.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RCM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
R1 RCM (RCM) Company Description:
R1 RCM, Inc. engages in the provision of revenue cycle management to healthcare providers. It offers end-to-end, modular revenue cycle, and physician advisory services. The company was founded by Mary Ann Tolan and J. Michael Cline in July 2003 and is headquartered in Chicago, IL.
Read More on RCM:
- R1 RCM downgraded to Sector Weight from Overweight at KeyBanc
- R1 RCM price target lowered to $15 from $17 at Guggenheim
- R1 RCM to Release First Quarter 2024 Results on May 8, 2024
- R1 Releases Fourth Annual Environmental, Social and Governance (ESG) Report
- R1 RCM price target lowered to $16 from $17 at Canaccord
